Christina Nault

Tacrine was originally brought to the market in 1993 as an acetylcholinesterase inhibitor to fight the symptoms of Alzheimer disease.

Although the treatment of motor symptoms is the primary focus of care for Parkinson disease, helping these patients with sleep disorders is vital because of the impact on quality of life.

Antioxidants are capable of converting highly destructive free radicals and nonradical molecules, thereby reducing cerebral stress.

Pharmacists are an essential part of improving care for patients with epilepsy.

With the help of pharmacists and a team of health care providers, a better quality of life is possible for patients with Parkinson disease.

Deucravacitinib is a possible solution for patients with psoriasis who wish to have the convenience of an oral medication.